{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T13:20:07Z","timestamp":1792329607820,"version":"4.4.0"},"reference-count":45,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>Oxazolidinone antibiotics\u2014linezolid and tedizolid\u2014are often used to treat multidrug-resistant infections. They are highly bioavailable and ideal for transition to enteral therapy when appropriate. However, multiple associated adverse effects are potentially treatment-limiting. The objective of this review is to discuss relevant adverse effects of linezolid and tedizolid, including serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis, and their commonality in real-world experience in the last decade. Mitigation strategies, including the role of therapeutic drug monitoring, are also discussed.<\/jats:p>","DOI":"10.1017\/ash.2024.487","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T10:09:33Z","timestamp":1737972573000},"source":"Crossref","is-referenced-by-count":17,"title":["Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis"],"prefix":"10.1017","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-9575","authenticated-orcid":false,"given":"Adam","family":"Greenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1199-6791","authenticated-orcid":false,"given":"Erin","family":"Deja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1342-8252","authenticated-orcid":false,"given":"Sangeeta","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2983-1364","authenticated-orcid":false,"given":"Barry","family":"Rittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"S2732494X2400487X_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.09.051"},{"key":"S2732494X2400487X_ref41","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000534"},{"key":"S2732494X2400487X_ref30","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2147\/TCRM.S109444","article-title":"Safety of long-term use of linezolid: results of an open-label study","volume":"12","author":"Vazquez","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"S2732494X2400487X_ref23","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001216"},{"key":"S2732494X2400487X_ref42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-20"},{"key":"S2732494X2400487X_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.05.010"},{"key":"S2732494X2400487X_ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac331"},{"key":"S2732494X2400487X_ref27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00606-2015"},{"key":"S2732494X2400487X_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106783"},{"key":"S2732494X2400487X_ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.967311"},{"key":"S2732494X2400487X_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.12.009"},{"key":"S2732494X2400487X_ref37","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12797"},{"key":"S2732494X2400487X_ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.47426"},{"key":"S2732494X2400487X_ref40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03684-14"},{"key":"S2732494X2400487X_ref3","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050530"},{"key":"S2732494X2400487X_ref26","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0822"},{"key":"S2732494X2400487X_ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.946058"},{"key":"S2732494X2400487X_ref15","doi-asserted-by":"publisher","DOI":"10.1177\/08971900231182772"},{"key":"S2732494X2400487X_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106843"},{"key":"S2732494X2400487X_ref32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012114"},{"key":"S2732494X2400487X_ref24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00022912"},{"key":"S2732494X2400487X_ref44","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac028"},{"key":"S2732494X2400487X_ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2021.10.007"},{"key":"S2732494X2400487X_ref20","first-page":"61","article-title":"Optic neuropathy associated with linezolid: systematic review of cases","volume":"43","author":"Brandariz-N\u00fa\u00f1ez","year":"2019","journal-title":"Farm Hosp"},{"key":"S2732494X2400487X_ref25","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"key":"S2732494X2400487X_ref33","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13245"},{"key":"S2732494X2400487X_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg109"},{"key":"S2732494X2400487X_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2019.09.002"},{"key":"S2732494X2400487X_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2022.09.008"},{"key":"S2732494X2400487X_ref19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00027-20"},{"key":"S2732494X2400487X_ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03542-z"},{"key":"S2732494X2400487X_ref22","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000783"},{"key":"S2732494X2400487X_ref1","unstructured":"1. Zyvox (linezolid) [package insert]. New York, NY: Pharmacia and Upjohn; August 2023."},{"key":"S2732494X2400487X_ref4","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.09r00853"},{"key":"S2732494X2400487X_ref2","unstructured":"2. Sivextro (tedizolid) [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; 2023."},{"key":"S2732494X2400487X_ref21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1320"},{"key":"S2732494X2400487X_ref43","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01282-23"},{"key":"S2732494X2400487X_ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03500-9"},{"key":"S2732494X2400487X_ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1178646919873925"},{"key":"S2732494X2400487X_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02990-1"},{"key":"S2732494X2400487X_ref17","doi-asserted-by":"publisher","DOI":"10.1086\/501356"},{"key":"S2732494X2400487X_ref13","unstructured":"13. U.S. Food and Drug Administration. (2016). FDA warns about several safety issues with opioid pain medicines; requires label changes. Accessed 3\/11\/24."},{"key":"S2732494X2400487X_ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1956461"},{"key":"S2732494X2400487X_ref6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatry"},{"key":"S2732494X2400487X_ref28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.127910"}],"container-title":["Antimicrobial Stewardship &amp; Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X2400487X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T10:09:38Z","timestamp":1737972578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X2400487X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"alternative-id":["S2732494X2400487X"],"URL":"https:\/\/doi.org\/10.1017\/ash.2024.487","relation":{},"ISSN":["2732-494X"],"issn-type":[{"value":"2732-494X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e20"}}